Testing multiple treatments for multiple myeloma after prior therapy
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma (MM) based on standard criteria
- Your day-to-day function is good enough for study visits (performance status 0–2)
- Side effects from your last cancer treatment are mostly gone (grade 1 or less)
- You can follow the study schedule for checkups and procedures
- You can meet strict infection, vaccine, and medication rules (especially around recent IV antibiotics and “live” vaccines)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
This trial tests a new drug called cevostamab for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
This trial tests whether a new drug called cevostamab, combined with two existing myeloma drugs (pomalidomide and dexamethasone), works better than standard treatment for people whose myeloma has returned or stopped responding to prior therapy. You would receive this combination to see if it helps control your disease.
This trial tests a new treatment for people with newly diagnosed multiple myeloma that has not been treated before. It looks at whether adding a targeted therapy to standard treatment helps control the disease better.
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.